21
Apr 2026
Psychotropic medication use rises significantly after Parkinson's disease diagnosis
Up to one in three people with Parkinson's disease use at least one psychotropic medication, a recent study from the University of Eastern Finland shows.
Stay Informed!
21
Apr 2026
Coffee impacts the gut-brain axis to improve mood and stress
New research from APC Microbiome Ireland, a world leading research centre at University College Cork, has comprehensively explored the mechanisms behind coffee's positive effects on the gut-brain axis for the first time.
21
Apr 2026
Molecular keyhole discovery offers new hope for personalized pain therapies
Researchers at VIB, VUB, and KU Leuven have identified a tiny binding site, a molecular 'keyhole', in the TRPM3 ion channel, a crucial sensor in pain signaling.
21
Apr 2026
Geo-mapping to identify high-need areas for trauma blood delivery
Research shows geomapping can pinpoint trauma hotspots, optimizing prehospital blood supply deployment and potentially saving lives in urgent care scenarios.
21
Apr 2026
Rising colorectal cancer rates in young Swiss adults spark concern
While the incidence of colorectal cancer is decreasing among those over 50, it is rising at an alarming rate among younger individuals, sometimes as early as their thirties.
21
Apr 2026
Democrats demand Trump administration halt plan to collect federal workers’ health data
Democratic lawmakers are demanding that the Trump administration halt plans to collect sensitive medical records for millions of federal workers and retirees, as well as their family members.
21
Apr 2026
AI chatbots give misleading health advice nearly half the time
Widespread inaccuracies in AI chatbot health responses pose public health risks, highlighting the urgent need for better oversight and cleaner training data.
21
Apr 2026
Alzheimer’s monoclonal antibodies fail to deliver meaningful results
Despite reducing amyloid plaques, antibody treatments for Alzheimer's fail to improve cognition, highlighting critical gaps in current therapeutic approaches.
21
Apr 2026
Last patient has completed AlzeCure's Phase Ib clinical study with NeuroRestore ACD856
AlzeCure Pharma AB (publ), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that the last patient’s last visit (LPLV) has now occurred in the ongoing Phase Ib clinical trial of ACD856, the lead drug candidate within the NeuroRestore platform, which is being developed for Alzheimer’s disease and other indications.
21
Apr 2026
Long-term exposure to air pollution (PM2.5) raises risk of developing cancer by 11 % and of dying from cancer by 12 %
The Union for International Cancer Control (UICC), with support from the Clean Air Fund, has released a global report, Clean air in cancer control: An overview of the evidence, presenting data on the scale of cancer risk and mortality from polluted air.
